News und Analysen

The S&P 500 has gained 17% year to date after a constellation of factors has lifted investor sentiment, including better-than-expected earnings and stronger-than-expected economic growth. The index

Stocks are rarely "on sale" without good reason. In this case, both of these stocks have disappointed the market recently with their earnings reports. That's why their share prices have declined

If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.

Generic drug

The Gap (NYSE: GPS) has been on the decline for many years now. It's still one of the largest apparel companies in the U.S., but it has struggled to generate growth for any of its well-known brands

Given recent market weakness, it makes sense to start looking at buying stocks unduly sold off recently. That's why I think GE HealthCare Technologies (NASDAQ: GEHC),  Johnson Controls (NYSE: JCI),

A pronounced decline in quarterly sales sent Nordstrom (NYSE: JWN) investors heading for the exits on the last trading day of the week. The storied retailer's stock price was down by almost 8% in

Image source: The Motley Fool.

Gap (NYSE: GPS)Q2 2023 Earnings CallAug 24, 2023, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Nordstrom (NYSE: JWN)Q2 2023 Earnings CallAug 24, 2023, 4:45 p.m. ET

Operator

Continue reading

Source Fool.com

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).

Both companies offer

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

The stock market is on a tear in 2023, led mostly by the technology sector. But we've just entered the weakest seasonal period of the year for stocks; August and September are the two worst months

Electric vehicle (EV) sales are continuing to accelerate. According to some research, EVs could represent upwards of 20% of total new vehicle sales in 2023, up from 14% in 2022 and just 5% in 2020.

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

Apple component supplier Qorvo (NASDAQ: QRVO) has underperformed the broader market in 2023 so far, recording gains of just 17% compared to the Nasdaq Composite's gains of 33%. But that may be about

Brick-and-mortar fashion retailer Gap's (NYSE: GPS) stock is back in fashion with investors, up 24% in the past three months, even though sales from its clothing line are still underwhelming. At the

The Invesco QQQ (NASDAQ: QQQ) ETF has been on a tear so far in 2023. Here's what history shows as a possibility for what could happen next. Of course, technical analysis is not some magical crystal

Shares of Capri Holdings (NYSE: CPRI) were up 56% at 10:08 a.m. ET on Thursday after Tapestry agreed to acquire the company for $57 per share for a total value of $8.5 billion. The companies will

The stock market got off to a strong start Thursday morning, as major stock market benchmarks climbed as much as 1% at the open. Investors were generally pleased as year-over-year consumer inflation

Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines

Zions Bancorporation (NASDAQ: ZION) rewarded investors in July as its stock price surged 42% higher in the month, according to S&P Global Market Intelligence. Zions Bancorp is still down about 22%

Major lithium producers Albemarle (NYSE: ALB) and Livent (NYSE: LTHM) reported their second-quarter 2023 results this past week. So investors can now compare their results in their lithium